PE20091344A1 - Arilindenopirimidinas como antagonistas del receptor a2a de adenosina - Google Patents
Arilindenopirimidinas como antagonistas del receptor a2a de adenosinaInfo
- Publication number
- PE20091344A1 PE20091344A1 PE2008001819A PE2008001819A PE20091344A1 PE 20091344 A1 PE20091344 A1 PE 20091344A1 PE 2008001819 A PE2008001819 A PE 2008001819A PE 2008001819 A PE2008001819 A PE 2008001819A PE 20091344 A1 PE20091344 A1 PE 20091344A1
- Authority
- PE
- Peru
- Prior art keywords
- disease
- adenosine
- receptor
- arylindenopyrimidines
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 title 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98224707P | 2007-10-24 | 2007-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091344A1 true PE20091344A1 (es) | 2009-09-24 |
Family
ID=40091927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001819A PE20091344A1 (es) | 2007-10-24 | 2008-10-23 | Arilindenopirimidinas como antagonistas del receptor a2a de adenosina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8017614B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2217575A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011500819A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101835759A (cg-RX-API-DMAC7.html) |
| AR (1) | AR069009A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008317034A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2008003131A1 (cg-RX-API-DMAC7.html) |
| PA (1) | PA8801501A1 (cg-RX-API-DMAC7.html) |
| PE (1) | PE20091344A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200934493A (cg-RX-API-DMAC7.html) |
| UY (1) | UY31420A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009055308A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110105540A1 (en) * | 2009-10-29 | 2011-05-05 | Jackson Paul F | 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST |
| US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
| JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
| AU2020205753B2 (en) | 2019-01-11 | 2025-05-29 | Omeros Corporation | Methods and compositions for treating cancer |
| CA3256033A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127510A1 (en) | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
| ATE429421T1 (de) | 2003-10-03 | 2009-05-15 | Ortho Mcneil Pharm Inc | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten |
-
2008
- 2008-10-17 WO PCT/US2008/080256 patent/WO2009055308A1/en not_active Ceased
- 2008-10-17 EP EP08841238A patent/EP2217575A1/en not_active Withdrawn
- 2008-10-17 CN CN200880112882A patent/CN101835759A/zh active Pending
- 2008-10-17 AU AU2008317034A patent/AU2008317034A1/en not_active Abandoned
- 2008-10-17 JP JP2010531141A patent/JP2011500819A/ja not_active Withdrawn
- 2008-10-17 US US12/253,358 patent/US8017614B2/en not_active Expired - Fee Related
- 2008-10-23 AR ARP080104625A patent/AR069009A1/es not_active Application Discontinuation
- 2008-10-23 CL CL2008003131A patent/CL2008003131A1/es unknown
- 2008-10-23 PA PA20088801501A patent/PA8801501A1/es unknown
- 2008-10-23 TW TW097140560A patent/TW200934493A/zh unknown
- 2008-10-23 PE PE2008001819A patent/PE20091344A1/es not_active Application Discontinuation
- 2008-10-24 UY UY31420A patent/UY31420A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101835759A (zh) | 2010-09-15 |
| WO2009055308A1 (en) | 2009-04-30 |
| AU2008317034A1 (en) | 2009-04-30 |
| EP2217575A1 (en) | 2010-08-18 |
| CL2008003131A1 (es) | 2010-02-19 |
| JP2011500819A (ja) | 2011-01-06 |
| TW200934493A (en) | 2009-08-16 |
| UY31420A1 (es) | 2009-04-30 |
| US8017614B2 (en) | 2011-09-13 |
| AR069009A1 (es) | 2009-12-23 |
| PA8801501A1 (es) | 2009-05-15 |
| US20090111827A1 (en) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010001837A (es) | Derivados de 4-pirimidinasulfamida. | |
| CR11554A (es) | Pirrolo-Pirimidinas y Pirrolo-Piridinas | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| CU20120013A7 (es) | Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| NI201300068A (es) | Moduladores del receptor de glucagón | |
| UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
| CL2012001348A1 (es) | Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| AR078434A1 (es) | Sales de tetrazol-1-il- fenoximetil-tiazol-2-il- piperinidil- pirimidina sustituida | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
| AR067328A1 (es) | Formas amorfas estabilizadas de mesilato de imatinib | |
| PE20091344A1 (es) | Arilindenopirimidinas como antagonistas del receptor a2a de adenosina | |
| CR10963A (es) | Compuestos de 2-amino pirimidina | |
| MX390264B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| DOP2006000076A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
| UY30558A1 (es) | Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos | |
| AR057222A1 (es) | Agonistas del receptor del neuropeprtido -2 | |
| NO20090779L (no) | 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister | |
| CL2016001348A1 (es) | Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras. | |
| UY30916A1 (es) | Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros | |
| TN2011000428A1 (en) | Uses of nk receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |